Avid Bioservices Inc (CDMO)

[entdoc]

most amazing part of PPHM narrative is how the anti-aminophospholipid (anti-PS, Bavituximab) platform is growing, and is not becoming obsolete. When a "discovery" is deemed obvious, and becomes a part of the background, then it is truly revolutionary. Startling is how the heads of the PPHM anti-PS hydra are budding so fast and growing. The platform grows more and more solid. Unfortunately, as I posted almost a decade ago, PPHM stock trades like a public utility. Ironic, huh.